New therapies in SLE.
The therapy of systemic lupus erythematosus (SLE), a systemic autoimmune disease of unknown aetiology, is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities. Recent preclinical studies have shown the therapeutic efficacy of several drugs and/or new compounds, some of which have been tested in clinical trials. This review provides an update on the use of new approaches in SLE and recent patents that could develop into novel therapeutics available to the clinical armamentarium for the management of the disease.
Ferrera
Francesca
F
Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Filaci
Gilberto
G
Rizzi
Marta
M
Singh
Ram P
RP
Indiveri
Francesco
F
Hahn
Bevra H
BH
La Cava
Antonio
A
D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D010330:Patents as Topic
D007166:Immunosuppressive Agents